审查当前的非侵入性皮罗尼病管理:一个不断变化的现实
Jaime Garre-Hernanz1, María Moyano-Maqueda1, José Marenco2
1Department of Urology, Hospital de Mérida, 06800 Mérida, Spain.
Archivos espanoles de urologia
|July 11, 2025
概括
由于证据有限,皮罗尼病 (PD) 的治疗具有挑战性. 内射治疗显示出有前途,但取消原酶Clostridium Histolyticum (CCH) 留下了一个空白,阴茎引疗法作为一种补充选择.
科学领域:
- 安德罗学与人类学
- 泌尿器科 泌尿器科 泌尿器科 泌尿器科
- 纤维化疾病 纤维化疾病
背景情况:
- 皮罗尼氏病 (PD) 影响2%-9%的成年男性,导致阴茎曲,并可能影响性功能.
- 由于许多选择和有限的高质量证据,PD的治疗是复杂的,这阻碍了泌尿病学建议.
- 目前的国际指导方针受到随机试验的缺乏,小患者队列和不良遵守的阻碍.
研究的目的:
- 提供基于证据的对目前佩罗尼病的非侵入性治疗方法的综述.
- 突出最近的临床实践和PD管理中的相关临床试验.
- 评估PD新兴疗法的疗效和潜力.
主要方法:
- 对PD管理当前的临床实践进行全面审查.
- 对正在进行的皮罗尼病治疗临床试验的分析.
- 评估支持各种非侵入性治疗选择的证据.
主要成果:
- 内部治疗在非侵入性PD治疗中提供了最强有力的证据.
- 美国食品和药物管理局 (FDA) 唯一批准的药物原酶Clostridium Histolyticum (CCH) 的撤销,已经取消了一个关键的第一线选择.
- 阴茎引疗法正在成为一个有前途的补充方法,有可能改善治疗结果.
结论:
- 对皮罗尼病的非侵入性治疗需要进一步进行强有力的临床研究.
- 病发病治疗的格局正在不断变化,需要有效和可访问的选择.
- 阴茎引疗法值得考虑作为其他PD治疗的辅助.
更多相关视频
03:55Urethroplasty with Pedicled Tunica Vaginalis for the Treatment of Long-segment Anterior Urethral Stricture Caused by Lichen Sclerosus of Glans Penis
Published on: October 18, 2024
282
03:37Iatrogenic Injury Recapitulated: Electroexcision Technique for Urethral Stricture Modeling in Rats
Published on: October 11, 2024
463
相关概念视频
01:27Peripheral Artery Disease III: Interprofessional Care
32
Peripheral Artery Disease (PAD) is characterized by narrowed arteries that diminish blood flow to the extremities. Effective management of PAD requires an interprofessional approach involving various healthcare professionals. The critical aspects of interprofessional care for PAD patients focus on risk factor modification, drug therapy, exercise therapy, nutrition therapy, critical limb ischemia care, and interventional radiology and surgical procedures.The primary treatment goal for PAD...
32
01:28Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors
254
Phosphodiesterase 5 (PDE5) inhibitors are potent enzymes that function to hydrolyze cyclic nucleotides to their corresponding 5' monophosphates. Their unique biochemical properties have been applied in treating Pulmonary Arterial Hypertension (PAH).
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
254
01:26Angina IV: Management
28
IntroductionThe management of angina requires a comprehensive approach that includes pharmacological therapies, medical procedures, and lifestyle modifications.Pharmacological TherapiesAntiplatelet agents, such as aspirin, clopidogrel, prasugrel, and ticagrelor, play a pivotal role in preventing thrombus formation in patients with angina. These medications inhibit platelet aggregation and reduce the likelihood of myocardial infarction and other cardiovascular events.Anticoagulants, including...
28
01:26Atherosclerosis III: Management
41
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
41
01:23Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
258
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
258
01:17Pericarditis III: Medical Management
28
The primary objectives of managing pericarditis are to determine the underlying cause, provide effective therapy for treatment and symptom relief, and promptly detect signs and symptoms of cardiac tamponade. The following outlines the essential aspects of medical management for pericarditis:ObjectivesDetermine the Cause: Identifying the underlying cause of pericarditis is crucial for targeted treatment. Causes include viral infections, autoimmune diseases, post-cardiac injury syndrome, and...
28